Cetuximab enhances TRAIL-induced gastric cancer cell apoptosis by promoting DISC formation in lipid rafts

Biochemical and Biophysical Research Communications

Volumn 439, Issue 2, 2013, Pages 285-290

  Xu, Ling ^a   Hu, Xuejun ^a   Qu, Xiujuan ^a   Hou, Kezuo ^a   Zheng, Huachuan ^a   Liu, Yunpeng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cetuximab; DISC; Gastric cancer; Lipid rafts; TRAIL

Indexed keywords

BETA CYCLODEXTRIN; CASPASE 8; CETUXIMAB; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR 4; FAS ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIPID RAFT; PRIORITY JOURNAL; PROTEIN CLEAVAGE; STOMACH CANCER; WESTERN BLOTTING;

CETUXIMAB; DISC; GASTRIC CANCER; LIPID RAFTS; TRAIL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DRUG SYNERGISM; HUMANS; MEMBRANE MICRODOMAINS; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STOMACH; STOMACH NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84884281215     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.08.040     Document Type: Article

References (28)

1. Trarbach T., Moehler M., Heinemann V., Köhne C.H., Przyborek M., Schulz C., Sneller V., Gallant G., Kanzler S. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br. J. Cancer 2010, 102:506-512.
2. Greco F.A., Bonomi P., Crawford J., Kelly K., Oh Y., Halpern W., Lo L., Gallant G., Klein J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008, 61:82-90.
3. Younes A., Vose J.M., Zelenetz A.D., Smith M.R., Burris H.A., Ansell S.M., Klein J., Halpern W., Miceli R., Kumm E., Fox N.L., Czuczman M.S. A phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br. J. Cancer 2010, 103:1783-1787.
4. Cho I.R., Koh S.S., Min H.J., Park E.H., Srisuttee R., Jhun B.H., Kang C.D., Kim M., Johnston R.N., Chung Y.H. Reovirus infection induces apoptosis of TRAIL-resistant gastric cancer cells by down-regulation of Akt activation. Int. J. Oncol. 2010, 36:1023-1030.
5. Bellail A.C., Tse M.C., Song J.H., Phuphanich S., Olson J.J., Sun S.Y., Hao C. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J. Cell Mol. Med. 2010, 14:1303-1317.
6. Ouyang W., Yang C., Zhang S., Liu Y., Yang B., Zhang J., Zhou F., Zhou Y., Xie C. Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells. Int. J. Oncol. 2013, 42:699-711.
7. Morizot A., Mérino D., Lalaoui N., Jacquemin G., Granci V., Iessi E., Lanneau D., Bouyer F., Solary E., Chauffert B., Saas P., Garrido C., Micheau O. Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ. 2011, 18:700-711.
8. Lacour S., Micheau O., Hammann A., Drouineaud V., Tschopp J., Solary E., Dimanche-Boitrel M.T. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 2003, 22:1807-1816.
9. Suzuki K.G. Lipid rafts generate digital-like signal transduction in cell plasma membranes. Biotechnol J. 2012, 7:753-761.
10. Gajate C., Gonzalez-Camacho F., Mollinedo F. Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochem. Biophys. Res. Commun. 2009, 380:780-784.
11. Xu L., Qu X., Zhang Y., Hu X., Yang X., Hou K., Teng Y., Zhang J., Sada K., Liu Y. Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. FEBS Lett. 2009, 583:943-948.
12. Kyriakakis E., Maslova K., Frachet A., Ferri N., Contini A., Pfaff D., Erne P., Resink T.J., Philippova M. Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts. Cell. Signal. 2013, 25:1044-1053.
13. Irwin M.E., Mueller K.L., Bohin N., Ge Y., Boerner J.L. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J. Cell Physiol. 2011, 226:2316-2328.
14. Xu L., Zhang Y., Liu J., Qu J., Hu X., Zhang F., Zheng H., Qu X., Liu Y. TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells. Eur. J. Cancer 2012, 48:3288-3299.
15. Bremer E., Samplonius D.F., van Genne L., Dijkstra M.H., Kroesen B.J., de Leij L.F., Helfrich W. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J. Biol. Chem. 2005, 280:10025-10033.
16. Xu L., Qu X., Luo Y., Zhang Y., Liu J., Qu J., Zhang L., Liu Y. Epirubicin enhances TRAIL-induced apoptosis in gastric cancer cells by promoting death receptor clustering in lipid rafts. Mol. Med. Rep. 2011, 4:407-411.
17. Carlisi D., Lauricella M., D'Anneo A., Emanuele S., Angileri L., Di Fazio P., Santulli A., Vento R., Tesoriere G. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur. J. Cancer 2009, 45:2425-2438.
18. Choi H., Chang J.W., Jung Y.K. Peroxiredoxin 6 interferes with TRAIL-induced death-inducing signaling complex formation by binding to death effector domain caspase. Cell Death Differ. 2011, 18:405-414.
19. Lacour S., Hammann A., Grazide S., Lagadic-Gossmann D., Athias A., Sergent O., Laurent G., Gambert P., Solary E., Dimanche-Boitrel M.T. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 2004, 64:3593-3598.
20. Gajate C., Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007, 109:711-719.
21. Gajate C., Gonzalez-Camacho F., Mollinedo F. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS One 2009, 4:e5044.
22. Psahoulia F.H., Drosopoulos K.G., Doubravska L., Andera L., Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol. Cancer Ther. 2007, 6:2591-2599.
23. Montuori N., Bifulco K., Carriero M.V., La Penna C., Visconte V., Alfano D., Pesapane A., Rossi F.W., Salzano S., Rossi G., Ragno P. The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor. Cell Mol. Life Sci. 2011, 68:2453-2467.
24. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359:1757-1765.
25. Gibson N.J., Tolbert L.P., Oland L.A. Roles of specific membrane lipid domains in EGF receptor activation and cell adhesion molecule stabilization in a developing olfactory system. PLoS One 2009, 4:e7222.
26. Van Schaeybroeck S., Kelly D.M., Kyula J., Stokesberry S., Fennell D.A., Johnston P.G., Longley D.B. Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. Cancer Res. 2008, 68:8312-8321.
27. Irwin M.E., Bohin N., Boerner J.L. Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells. Cancer Biol. Ther. 2011, 12:718-726.
28. Poh T.W., Huang S., Hirpara J.L., Pervaiz S. LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization DISC assembly, and mitochondrial permeabilization. Cell Death Differ. 2007, 14:1813-1825.